Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 4/2013

01-08-2013 | Nephrology - Original Paper

High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients

Authors: Tanja Antunovic, Aleksandra Stefanovic, Marina Ratkovic, Branka Gledovic, Najdana Gligorovic-Barhanovic, Dragica Bozovic, Jasmina Ivanisevic, Milica Prostran, Marina Stojanov

Published in: International Urology and Nephrology | Issue 4/2013

Login to get access

Abstract

Purpose

We investigated the role of serum uric acid (sUA) and superoxide dismutase (SOD) as predictive factors for mortality in hemodialysis (HD) patients.

Methods

SOD, butyrylcholinesterase, and malondialdehyde were estimated spectrophotometrically and the other parameters by standard procedures. High-sensitive C-reactive protein was assayed by a sandwich ELISA method.

Results

sUA among survivors (112.1 ± 13.82 μmol/L) was significantly lower than in deceased (160.8 ± 16.81 μmol/L, p < 0.001), while SOD was higher in survivors (31.8 ± 6.61 kU/L) than among deceased (20.2 ± 3.03, p < 0.05). Kaplan–Meier survival curves showed the greatest mortality risk in the highest tertile of basal sUA concentration (≥127.11 μmol/L, p < 0.001), and for SOD in the lowest tertile (≤23.83 kU/L, p < 0.05).

Conclusion

Our results suggest that high sUA and low SOD may predict all-cause and cardiovascular mortality in HD patients.
Literature
1.
Sombolos K, Tsitamidou Z, Kyriazis G, Karagianni A, Kanteropoulou M, Progia E (1997) Clinical evaluation of four different high-flux hemodialysers under conventional conditions in vivo. Am J Nephrol 17:406–412PubMedCrossRef
2.
Feig DI, Johnson RJ (2003) Hyperuricemia in childhood primary hypertension. Hypertension 42:247–252PubMedCrossRef
3.
Feig DI, Soletsy B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932PubMedCrossRef
4.
Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811–1821PubMedCrossRef
5.
Lin JD, Chiou WK, Chang HY, Liu FH, Weng HF (2007) Serum uric acid and leptin levels in metabolic syndrome: a quandary over the role of uric acid. Metabolism 56:751–756PubMedCrossRef
6.
Dawson J, Walters M (2006) Uric acid and xanthine oxidase: future therapeutic targets in prevention of cardiovascular disease? Br J Clin Pharmacol 62:633–644PubMedCrossRef
7.
Hozawa A, Folsom AR, Ibrahim H, Javier Nieto F, Rosamond WD, Shahar E (2006) Serum uric acid and risk of ischemic stroke: the ARIC Study. Atherosclerosis 187:401–407PubMedCrossRef
8.
Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1071–1992. National Health and Nutrition Examination Surve. JAMA 283:2404–2410PubMedCrossRef
9.
Annuk M, Zilmer M, Fellistro B (2003) Endothelium-dependent vasodilatation and oxidative stress in chronic renal failure: impact on cardiovascular disease. Kidney Int 63:S50–S53CrossRef
10.
Sies H (1997) Oxidative stress: oxidants and antioxidants. Exp Physiol 82:291–295PubMed
11.
Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Yoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18:1272–1280PubMedCrossRef
12.
Ramos R, Martinez-Castelao A (2008) Lipoperoxidation and hemodialysis. Metab Clin Exp 57:1369–1374PubMedCrossRef
13.
Suresh DR, Delphine S, Agarwai R (2008) Biochemical markers of oxidative stress in predialytic chronic renal failure patients. Hong Kong J Nephrol 10:69–73CrossRef
14.
Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH (2002) Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 33:1048–1052PubMedCrossRef
15.
Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A (2007) A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid acute ischemic stroke. Stroke 38:2173–2175PubMedCrossRef
16.
Felström BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395–1407CrossRef
17.
Chan KE, Ikzler A, Gamboa GL et al (2011) Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int 80:978–985PubMedCrossRef
18.
Alcantara VM, Chautard-Freire-Maia EA, Scartezini M, Cerci MS, Braun-Prado K, Picheth G (2002) Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest 62:399–404PubMedCrossRef
19.
Stojanov M, Stefanovic A, Dzingalasevic G, Mandic-Radic S, Prostran M (2011) Butyrylcholinesterase activity in young men and women: association with cardiovascular risk factors. Clin Biochem 44:623–626PubMedCrossRef
20.
Garsia SC, Wyse ATS, Valentini J et al (2008) Butyrylcholinesterase activity is reduced in hemodialysis patients: is there association with hyperhomocysteinemia and/or oxidative stress? Clin Biochem 41:474–479CrossRef
21.
Stojanov MD, Jovicic DM, Djuric SP, Konjevic MM, Todorovic ZM, Prostram MS (2009) Butyrylcholinesterase activity and mortality risk in hemodialysis patients: comparison to hsCRP and albumin. Clin Biochem 42:22–26PubMedCrossRef
22.
Mekki K, Taleb W, Bouzidi N, Kaddous A, Bouchenak M (2010) Effect of hemodialysis and peritoneal dialysis on redox status in chronic renal failure patients: a comparative study. Lipids Health Dis 9:93–99PubMedCrossRef
23.
Zvolińska D, Grzeszczak W, Kiliś-Pstrusińska K, Szprynger K, Szczepańska M (2004) Lipid peroxidation and antioxidant enzymes in children with chronic renal failure. Pediatr Nephrol 19:888–892CrossRef
24.
Hambali Z, Ahmad Z, Arab S, Khazaai H (2011) Oxidative stress and its association with cardiovascular disease in chronic renal failure patients. Indian J Nephrol 21:21–25
25.
26.
Matsuoka H (2001) Endothelial dysfunction associated with oxidative stress in human. Diabetes Res Clin Pract 54:S65–S72PubMedCrossRef
27.
Heltzer T, Schlizing T, Krohn K, Meinertz T, Munzel T (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673–2678CrossRef
28.
Madero M (2008) High levels of uric acid linked to CKD death risk. Renal Urol News July 11
29.
Hsu SP, Pai MF, Peng YS, Chiang CK, Ho TI, Hung KY (2004) Serum uric acid show a “J-shaped” association with all-cause mortality in hemodialysis patients. Nephrol Dial Transplant 19:457–462PubMedCrossRef
30.
Backer BF (1993) Towards the physiological function of uric acid. Free Radic Biol Med 14:615–631CrossRef
31.
Ginsberg MH, Kozin F, O’Malley M, Mc Carty DJ (1977) Release of platelet constituents by monosodium urate crystals. J Clin Invest 60:999–1007PubMedCrossRef
32.
De Scheerder JK, van de Kraay AM, Lamers JM, Koster JF, de Jong JW, Serruys PW (1991) Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 68:392–395PubMedCrossRef
33.
Ramos R, Martinez-Castelao A (2008) Lipoperoxidation and hemodialysis. Metab Clin Exp 57:1369–1374PubMedCrossRef
34.
Bagnati M, Perugini C, Cau C, Borbone R, Albano E, Bellomo G (1999) When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation; a study using uric acid. Biochem J 15:143–152CrossRef
35.
Perugini C, Seccia M, Albano E, Bellomo G (1997) The dynamic reduction of Cu(II) to Cu(I) and not Cu(I) availability is sufficient trigger for low density lipoprotein oxidation. Biochim Biophys Acta 1347:191–198PubMedCrossRef
36.
Tonelli M, Wiebe N, Hemmelgarn B et al (2009) Trace elements in hemodialysis patients: a systematic review and meta-analysis. BMC Med 7:25–37PubMedCrossRef
37.
Santos CXC, Anjos EI, Augusto O (1999) Uric acid oxidation by peroxinitrite:multiple reactions, free radical formation, and amplification of lipid oxidation. Arch Biochem Biophys 372:285–294PubMedCrossRef
38.
Abuja PM (1999) Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Lett 446:305–308PubMedCrossRef
Metadata
Title
High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients
Authors
Tanja Antunovic
Aleksandra Stefanovic
Marina Ratkovic
Branka Gledovic
Najdana Gligorovic-Barhanovic
Dragica Bozovic
Jasmina Ivanisevic
Milica Prostran
Marina Stojanov
Publication date
01-08-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0233-x

Other articles of this Issue 4/2013

International Urology and Nephrology 4/2013 Go to the issue

Urology - Original Paper

Analysis of female voiding dysfunction: a prospective, multi-center study

Urology - Original Paper

Correlation of 99mTc-DMSA scan with radiological and laboratory examinations in childhood acute pyelonephritis: a time-series study

Nephrology - Original Paper

CDK-EPI equation may be the most proper formula based on creatinine in determining glomerular filtration rate in Chinese patients with chronic kidney disease

Urology - Original Paper

Urinary turbidity as a marker of crystallization: Is spectrophotometric assessment useful?

Urology - Case Report

Bleeding renal angiomyolipoma presenting as duodenal obstruction

Urology - Original Paper

Cystoscopically guided percutaneous suprapubic cystolitholapaxy in children
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits